Aytu BioScience Inc (OTCMKTS: AYTU)
When it comes to the world of micro-caps, one of the biggest problems tends to be communication with investors. Small companies just don’t seem to update their investors quite as much as the larger companies. However, Aytu BioScience seems to be breaking that mold. In fact, in just the 2 weeks or so, the company has released 4 press releases, providing investors with updates. So, here we are after these releases, and I figured it would be fun to put it all together. Below, we’ll talk about recent releases, what it all points to, and whether or not AYTU should be on your watch list.
January 18th: AYTU Announces 2 Presentations
On January 18th, Aytu BioScience announced that it would be giving two poster presentations. The presentations. The presentations demonstrate clinical data surrounding Atesto(R) (testosterone) Nasal Gel. This demonstrates that the data has been accepted for presentation at the American Urological Association 2017 Annual Meeting. The meeting will be held from May 12th to May 16th in Boston, MA. In a statement, Josh Disbrow, CEO at AYTU had the following to offer…
“Natesto’s clinical benefits continue to be proven by studies such as the two accepted for presentation at the AUA, and Aytu is committed to continually growing Natesto’s body of scientific evidence through additional study with experts in the field of urology.”
January 24th: Investor Conference Announced
On January 24th, AYTU announced yet another presentation. The presentation was held on January 31st at 1:30 at NobleCon 13 – Noble Capital Markets. At this presentation, Josh Disbrow, Chairman and CEO and Jarrett Disbrow, OO provided a corporate overviews, keeping investors updated with regard to what’s going on with the company.
January 31st: Aytu BioScience Announces Presentation Of Operational Results
On January 31st, another presentation was announced. This presentation will be given on February 9th, 2017 at 4:30. At this presentation, Aytu BioScience will present its results for the second fiscal quarter of 2017. We’ll also be hearing a bit about recent accomplishments as well as the business and growth strategy from the top! If you’d like to join the call, you can dial into 1 (855) 656-0926 from the United States or 1 (412) 542-4198 from around the world.
February 1st: 2 More Presentations Announced
Most recently, on February 1st, AYTU announced 2 more coming presentations. These presentations will be held at the Endocrine Society 2017 Annual Meeting. The meeting takes place from April 1st through April 4th. The presentations surround the company’s clinical data associated with Natesto(R) (testosterone) Nasal Gel. In a statement, Josh Disbrow, CEO at Aytu BioScience had the following to offer…
“Clinical interest in the benefits of Natesto continues to build, evidenced by the acceptance of these two poster presentations at the Endocrine Society Annual Meeting, which follows the acceptance of two other posters for presentation at the American Urological Association Annual Meeting that we announced earlier…”
Bringing All Of This Together
Looking at the press releases above, two things become very clear. First and foremost, AYTU isn’t your average micro-cap biotechnology company when it comes to communication. In fact, just in the past two weeks, the company has announced two opportunities for investors to connect with management as well as get valuable insights into what’s happening at the company.
The second piece here is that the company is not only working hard on Natesto(R), they are driven by both the present and clear medical need for their products and the pride that comes along with their accomplishments. As a result, they have compiled data that is compelling that has led to the approval of data for several presentations. At the end of the day, this is definitely one for the watch list.
What Do You Think?
Where do you think AYTU is headed moving forward? Join the discussion in the comments below!
Recent Posts from Modest Money
- Using Forex Broker Reviews to Rate Forex Brokers
- Dividend Aristocrat Cardinal Health (CAH) Drops 12% – Buying Opportunity or Value Trap?
- 5 Reasons I Favor Junior Exploration Companies
- How Luxury Brands Like Gucci Stay Relevant in the Changing Times
- 4 Smart Money Moves for Getting Ahead Financially in Your 20s